Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis

Psoriasis is a chronic inflammatory, autoimmune-mediated disease that affects millions of individuals worldwide. Advances in treatment with biological agents represented by monoclonal antibodies, such as TNF-α inhibitors (TNFI), IL-17A and IL-12/23 antagonists have not only benefited from outstandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Anghel, Flavia, Nitusca, Diana, Cristodor, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703749/
https://www.ncbi.nlm.nih.gov/pubmed/34947847
http://dx.doi.org/10.3390/life11121316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703749/
https://www.ncbi.nlm.nih.gov/pubmed/34947847
http://dx.doi.org/10.3390/life11121316

Ejemplares similares